Last reviewed · How we verify
Doxorubicin Hydrochloride Liposome Injection+carboplatin
Doxorubicin Hydrochloride Liposome Injection+carboplatin is a Combination chemotherapy (anthracycline + platinum agent) Small molecule drug developed by Hunan Cancer Hospital. It is currently in Phase 3 development for Ovarian cancer, Breast cancer, Other solid tumors (under investigation in phase 3). Also known as: PP.
Doxorubicin liposome intercalates DNA to inhibit topoisomerase II while carboplatin forms DNA cross-links, together inducing apoptosis in cancer cells.
Doxorubicin liposome intercalates DNA to inhibit topoisomerase II while carboplatin forms DNA cross-links, together inducing apoptosis in cancer cells. Used for Ovarian cancer, Breast cancer, Other solid tumors (under investigation in phase 3).
At a glance
| Generic name | Doxorubicin Hydrochloride Liposome Injection+carboplatin |
|---|---|
| Also known as | PP |
| Sponsor | Hunan Cancer Hospital |
| Drug class | Combination chemotherapy (anthracycline + platinum agent) |
| Target | DNA (topoisomerase II for doxorubicin; DNA adducts for carboplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Doxorubicin hydrochloride liposome is an anthracycline that intercalates into DNA and inhibits topoisomerase II, preventing DNA unwinding and triggering cell death. Carboplatin is a platinum-based alkylating agent that forms intra- and inter-strand DNA cross-links, blocking replication and transcription. The liposomal formulation enhances doxorubicin delivery to tumors while reducing cardiotoxicity. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Ovarian cancer
- Breast cancer
- Other solid tumors (under investigation in phase 3)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Cardiotoxicity (reduced with liposomal formulation)
- Nephrotoxicity
- Peripheral neuropathy
Key clinical trials
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (PHASE2)
- A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer (PHASE1, PHASE2)
- Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer (PHASE3)
- Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer (PHASE4)
- Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer (PHASE3)
- Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial (PHASE3)
- TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer (PHASE3)
- A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Doxorubicin Hydrochloride Liposome Injection+carboplatin CI brief — competitive landscape report
- Doxorubicin Hydrochloride Liposome Injection+carboplatin updates RSS · CI watch RSS
- Hunan Cancer Hospital portfolio CI
Frequently asked questions about Doxorubicin Hydrochloride Liposome Injection+carboplatin
What is Doxorubicin Hydrochloride Liposome Injection+carboplatin?
How does Doxorubicin Hydrochloride Liposome Injection+carboplatin work?
What is Doxorubicin Hydrochloride Liposome Injection+carboplatin used for?
Who makes Doxorubicin Hydrochloride Liposome Injection+carboplatin?
Is Doxorubicin Hydrochloride Liposome Injection+carboplatin also known as anything else?
What drug class is Doxorubicin Hydrochloride Liposome Injection+carboplatin in?
What development phase is Doxorubicin Hydrochloride Liposome Injection+carboplatin in?
What are the side effects of Doxorubicin Hydrochloride Liposome Injection+carboplatin?
What does Doxorubicin Hydrochloride Liposome Injection+carboplatin target?
Related
- Drug class: All Combination chemotherapy (anthracycline + platinum agent) drugs
- Target: All drugs targeting DNA (topoisomerase II for doxorubicin; DNA adducts for carboplatin)
- Manufacturer: Hunan Cancer Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Ovarian cancer
- Indication: Drugs for Breast cancer
- Indication: Drugs for Other solid tumors (under investigation in phase 3)
- Also known as: PP